Physician profile
Robert Zenenberg
NPI 1245331834
$12,781.96
in general payments reported to CMS, 2019-2025
34 companies · $5,618 in 2025
The $5,618 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $337 · 2021: $1,176 · 2022: $1,877 · 2023: $1,341 · 2024: $1,609 · 2025: $5,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,541 · Consulting Fee: $3,600 · Travel and Lodging: $278 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,540.95 |
| Consulting Fee | $3,600.00 |
| Travel and Lodging | $277.84 |
| Education | $149.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $4,755.64 | 2019-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $1,260.10 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Vifor Pharma, INC. | $1,217.94 | 2019-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $847.32 | 2021-2025 | Benlysta, Jesduvroq, Shingrix |
| Amgen INC. | $838.01 | 2019-2025 | Tavneos, Repatha, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $511.78 | 2019-2025 | Jynarque, Voyxact |
| Opko Pharmaceuticals, LLC | $461.12 | 2021-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $236.88 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $222.77 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $221.51 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $216.43 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $210.45 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $191.98 | 2019-2023 | Krystexxa |
| Daiichi Sankyo INC. | $185.92 | 2019-2023 | Injectafer |
| Alexion Pharmaceuticals, INC. | $172.37 | 2019-2024 | Ultomiris |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $155.24 | 2019-2025 | |
| Genzyme Corporation | $153.99 | 2022-2025 | |
| Novo Nordisk INC | $144.13 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.43 | 2023-2025 | Jardiance |
| Azurity Pharmaceuticals, INC. | $111.72 | 2023-2025 | Edarbyclor, Edarbi, Edarbi |
| Fresenius USA Marketing, INC. | $85.19 | 2019-2024 | Velphoro |
| Ultragenyx Pharmaceutical INC. | $81.54 | 2020-2024 | Crysvita, Crysvita |
| Akebia Therapeutics INC | $70.06 | 2021-2024 | Vafseo, Auryxia |
| Ani Pharmaceuticals, INC. | $64.48 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $58.36 | 2022-2024 | Acthar |
| Invivyd INC | $33.46 | 2025 | Pemgarda |
| Cormedix INC. | $33.09 | 2025 | Defencath |
| Genentech USA, INC. | $27.77 | 2019 | |
| Shire North American Group INC | $24.19 | 2019 | |
| Cycle Pharmaceuticals INC | $16.41 | 2024 | Tiopronin |
| Watermark Medical, INC. | $15.58 | 2024 | |
| Lilly USA, LLC | $14.62 | 2025 | Jardiance |
| Strongbridge US INC. | $13.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Zenenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.